Institution-Grade Tools, Priced for Individual Investors.
Receive trading alerts directly to your inbox. Try Barchart Plus or Barchart Premier for free today.
/Meta%20Platforms%20by%20Primakov%20via%20Shutterstock.jpg)
/Alphabet%20(Google)%20Image%20by%20Markus%20Mainka%20via%20Shutterstock.jpg)
/AI%20(artificial%20intelligence)/AI%20technology%20-%20by%20Wanan%20Yossingkum%20via%20iStock.jpg)
/Palo%20Alto%20Networks%20Inc%20HQ%20sign-by%20Sundry%20Photography%20via%20Shutterstock.jpg)
Palo Alto Networks stock sinks as Anthropic’s leaked document reveals a breakthrough AI model. Here’s why the draft proved bearish for PANW shares on Friday.
TurboQuant introduces uncertainty for long-term memory demand, but SanDisk is set to benefit from tight supply conditions, sustained hyperscaler spending, and broad-based demand.
/Facebook-you've%20been%20Zucked%20by%20Annie%20Spratt%20via%20Unsplash.jpg)
Legal battles and massive AI spending are turning Meta into a risk-reward play.
/The%20CrowdStrike%20logo%20on%20an%20office%20building%20by%20bluestork%20via%20Shutterstock.jpg)
CrowdStrike shares sink as Anthropic hints at next-gen AI model with advanced cybersecurity capabilities. Here’s why CRWD stock is worth buying on the dip.
A war-driven oil rally is turning this overlooked small-cap into one of 2026’s biggest winners.
/Microsoft%20sign%20at%20the%20headquarters%20by%20VDB%20Photos%20via%20Shutterstock.jpg)
Analysts believe that this is not the bottom for this Magnificent Seven stock. MSFT is poised to rebound.
Lumentum continues to see sustained demand driven by AI, with several product lines delivering strong year-over-year growth.
WisdomTree had the highest Vol/OI ratio from Thursday’s options trading. The volume was not only 115.80 times the open interest on the Sept. 18 $15 call, but it was also more than eight times its average...
/A%20photo%20of%20a%20Sandisk%20Solid%20State%20Drive%20by%20Top%20Popular%20Vector%20by%20Shutterstock.jpg)
Could Google’s TurboQuant disrupt memory demand and shake Sandisk’s rally, or is this just noise? Should investors sell SNDK before momentum starts slipping?
Jazz Pharmaceuticals (JAZZ) is a specialty biopharma company focused on neuroscience and oncology. JAZZ exhibits strong technical momentum. Shares are up nearly 50% over the past year. The stock maintains...
